496 Pre-clinical development of a TCRm antibody targeting MHC-E complexes presenting signal peptides from classical MHC class I disrupts the NKG2A:MHC-E immune checkpoint and promotes anti-tumor immunity

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Regular and Young Investigator Award Abstracts

Topics

Biology

Cancer Oncology

Immunology

Mhc Class I

Major Histocompatibility Complex

Show all topics

DOI

10.1136/jitc-2024-sitc2024.0496